These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 19715444

  • 1. Emerging Raf inhibitors.
    McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M.
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):633-48. PubMed ID: 19715444
    [Abstract] [Full Text] [Related]

  • 2. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S, Flaherty KT.
    Expert Rev Mol Med; 2012 Oct 12; 14():e17. PubMed ID: 23058743
    [Abstract] [Full Text] [Related]

  • 3. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, Galvin K, Okaniwa M, Ishikawa T, Yoshida S.
    Cancer Res; 2013 Dec 01; 73(23):7043-55. PubMed ID: 24121489
    [Abstract] [Full Text] [Related]

  • 4. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA, Wilhelm S, Carter C, Kelley SL.
    Semin Oncol; 2006 Aug 01; 33(4):392-406. PubMed ID: 16890795
    [Abstract] [Full Text] [Related]

  • 5. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R, Piperdi S, Gorlick R.
    Clin Cancer Res; 2008 Oct 15; 14(20):6396-404. PubMed ID: 18927278
    [Abstract] [Full Text] [Related]

  • 6. Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling.
    Chen J, Shen Q, Labow M, Gaither LA.
    Cancer Res; 2011 Jun 15; 71(12):4280-91. PubMed ID: 21527556
    [Abstract] [Full Text] [Related]

  • 7. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT, McArthur G.
    Cancer; 2010 Nov 01; 116(21):4902-13. PubMed ID: 20629085
    [Abstract] [Full Text] [Related]

  • 8. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.
    J Pharmacol Exp Ther; 2009 Jun 01; 329(3):1063-70. PubMed ID: 19258520
    [Abstract] [Full Text] [Related]

  • 9. The role of the PI3K-AKT pathway in melanoma.
    Davies MA.
    Cancer J; 2012 Jun 01; 18(2):142-7. PubMed ID: 22453015
    [Abstract] [Full Text] [Related]

  • 10. Is B-Raf a good therapeutic target for melanoma and other malignancies?
    Madhunapantula SV, Robertson GP.
    Cancer Res; 2008 Jan 01; 68(1):5-8. PubMed ID: 18172288
    [Abstract] [Full Text] [Related]

  • 11. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ, Der CJ.
    Oncogene; 2007 May 14; 26(22):3291-310. PubMed ID: 17496923
    [Abstract] [Full Text] [Related]

  • 12. A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.
    Zipser MC, Eichhoff OM, Widmer DS, Schlegel NC, Schoenewolf NL, Stuart D, Liu W, Gardner H, Smith PD, Nuciforo P, Dummer R, Hoek KS.
    Pigment Cell Melanoma Res; 2011 Apr 14; 24(2):326-33. PubMed ID: 21176117
    [Abstract] [Full Text] [Related]

  • 13. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.
    Clin Cancer Res; 2006 Mar 15; 12(6):1785-93. PubMed ID: 16551863
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L, Trail PA, Taylor I, Wilhelm SM.
    Methods Enzymol; 2006 Mar 15; 407():597-612. PubMed ID: 16757355
    [Abstract] [Full Text] [Related]

  • 15. Resistance to MEK inhibitors: should we co-target upstream?
    Poulikakos PI, Solit DB.
    Sci Signal; 2011 Mar 29; 4(166):pe16. PubMed ID: 21447797
    [Abstract] [Full Text] [Related]

  • 16. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.
    King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, Kumar R, Rusnak DW, Takle AK, Wilson DM, Hugger E, Wang L, Karreth F, Lougheed JC, Lee J, Chau D, Stout TJ, May EW, Rominger CM, Schaber MD, Luo L, Lakdawala AS, Adams JL, Contractor RG, Smalley KS, Herlyn M, Morrissey MM, Tuveson DA, Huang PS.
    Cancer Res; 2006 Dec 01; 66(23):11100-5. PubMed ID: 17145850
    [Abstract] [Full Text] [Related]

  • 17. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.
    Panka DJ, Atkins MB, Mier JW.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 2):2371s-2375s. PubMed ID: 16609061
    [Abstract] [Full Text] [Related]

  • 18. BRAF inhibitors and melanoma.
    Flaherty KT.
    Cancer J; 2011 Apr 01; 17(6):505-11. PubMed ID: 22157295
    [Abstract] [Full Text] [Related]

  • 19. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
    Zafon C, Obiols G.
    Endocrinol Nutr; 2009 Apr 01; 56(4):176-86. PubMed ID: 19627734
    [Abstract] [Full Text] [Related]

  • 20. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
    Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, Carr D, Deng Y, Jin W, Black S, Long B, Liu J, Dinunzio E, Windsor W, Zhang R, Zhao S, Angagaw MH, Pinheiro EM, Desai J, Xiao L, Shipps G, Hruza A, Wang J, Kelly J, Paliwal S, Gao X, Babu BS, Zhu L, Daublain P, Zhang L, Lutterbach BA, Pelletier MR, Philippar U, Siliphaivanh P, Witter D, Kirschmeier P, Bishop WR, Hicklin D, Gilliland DG, Jayaraman L, Zawel L, Fawell S, Samatar AA.
    Cancer Discov; 2013 Jul 01; 3(7):742-50. PubMed ID: 23614898
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.